Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents

Santos, Neife Aparecida Guinaim dos; Ferreira, Rafaela Scalco; Santos, Antônio Cardozo dos

doi:10.1016/j.fct.2019.111079

Cited by 113 publications

(78 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cisplatin (CP) was the first heavy metal compound to be used as antineoplastic, and since its approval by the FDA in 1978, it is one of the most widely used for the treatment of various solid tumors such as lung, ovary, testis, bladder, head, and neck, and cervical and endometrial cancers [55,56].…”

Section: Cisplatin-induced Cytotoxicitymentioning

confidence: 99%

Oxytocin and Neuroprotective Effects

Erbaş¹,

Altuntaş²

2021

Oxytocin and Health

View full text Add to dashboard Cite

The neurohormone oxytocin (OT), consisting of nine amino acids, is produced in the hypothalamus and secreted from the posterior lobe of the pituitary gland. Recent studies show that OT can affect the course of the disease and is promising in the treatment of neurodegenerative disorders, due to its therapeutic properties and benefits. Histological and biochemical findings of the studies on vincristine-induced neuropathy, cisplatin-induced cytotoxicity, diabetic neuropathy, rotenone-induced Parkinson’s disease, hypoxia, and stroke, which are reviewed in this chapter, revealed that OT significantly prevented neuronal damage with its anti-inflammatory and antioxidant properties. Therefore, the neuroprotective effects of OT and the underlying molecular mechanisms continue to attract the attention of scientists.

show abstract

Section: Cisplatin-induced Cytotoxicitymentioning

confidence: 99%

Oxytocin and Neuroprotective Effects

Erbaş¹,

Altuntaş²

2021

Oxytocin and Health

View full text Add to dashboard Cite

show abstract

“…1), is a bifunctional chemotherapy drug that upon aquation of its two chloride leaving ligands and entry into cancer cell nuclei, typically forms intrastrand crosslinks with DNA causing the nucleotide strands to bend and alteration of gene transcription [1][2]. As cisplatin chemotherapy is frequently associated with severe side-effects [3][4][5][6], there has been considerable interest in identifying alternative platinum complexes that are toxic to cancer cells without causing severe side-effects. The monofunctional platinum(II) complex, cis-[Pt(NH 3 ) 2 Cl (phenanthridine)] + (phenanthriplatin; Fig.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β-catenin and TGF-β signaling

Monroe

Moolani

Irihamye

et al. 2021

Preprint

View full text Add to dashboard Cite

The monofunctional platinum(II) complex, phenanthriplatin, acts by blocking transcription, but its regulatory effects on long-noncoding RNAs (lncRNAs) have not been elucidated relative to traditional platinum-based chemotherapeutics, e.g., cisplatin. Here, we treated A549 non-small cell lung cancer and IMR90 lung fibroblast cells for 24 hours with either cisplatin, phenanthriplatin or a solvent control, and then performed microarray analysis to identify regulated lncRNAs. RNA22 v2 microRNA software was subsequently used to identify microRNAs (miRNAs) that might be suppressed by the most regulated lncRNAs. We found that miR-25-5p, -30a-3p, -138-5p, -149-3p, -185-5p, -378j, -608, -650, -708-5p, -1253, -1254, -4458, and − 4516, were predicted to target the cisplatin upregulated lncRNAs, IMMP2L-1, CBR3-1 and ATAD2B-5, and the phenanthriplatin downregulated lncRNAs, AGO2-1, COX7A1-2 and SLC26A3-1. The signaling pathways associated with these miRNAs suggests that phenanthriplatin may modulate Wnt/β-catenin and TGF-β signaling through the MAPK/ERK and PTEN/AKT pathways differently than cisplatin. Further, as some of these miRNAs may be subject to dissimilar lncRNA targeting in A549 and IMR90 cells, the monofunctional complex may not cause toxicity in normal lung compared to cancer cells by acting through distinct lncRNA and miRNA networks.

show abstract

“…Alternative regimens such as R‐GDP (rituximab, gemcitabine and cisplatin) or R‐ESHAP (rituximab, etoposide, methylprednisolone, cytarabine and cisplatin) may also be considered 8 . The main contraindications for platinum salts are kidney failure and hearing impairments 9,10 . All these dose‐intensive regimens contain platinum salts, which can harm patients with one or both of these comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

Abdayem

Ibrahim

Dakdouki

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Objectives To evaluate the efficacy and tolerability of an attenuated immunochemotherapy regimen based on cytarabine, etoposide and dexamethasone plus rituximab (R‐mini‐CYVE) in patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma (NHL). Methods We included pretreated adult patients with B‐cell NHL who were ineligible for high‐dose immunochemotherapy (HDT). Cytarabine and etoposide were given at four different dose levels, depending on the patient's frailty. Up to 8 cycles were administered. Results Between 2013 and 2019, 56 patients with diffuse large B‐cell lymphoma (n = 45, 80%) and indolent B‐cell lymphoma (n = 11, 20%) were included. Median age was 75 (range: 36‐88). Nineteen patients (35%) had a performance status ≥2. Patients received a median of 4 cycles of R‐mini‐CYVE. The objective response and the complete response rates were 50% and 33%, respectively. Median progression‐free survival and overall survival times were 5.7 (95% CI: 0.5‐10.9) and 14.7 (95% CI: 3.5‐25.9) months, respectively. Grade ≥3 anaemia, thrombocytopenia and neutropenia occurred in 44%, 55% and 60% of the patients, respectively. The most frequent non‐haematological grade ≥3 adverse events were sepsis (21%), fatigue (13%) and cytarabine‐related neurotoxicity (5%). Conclusion R‐mini‐CYVE demonstrated a meaningful antitumour efficacy and an acceptable safety profile in patients with relapsed/refractory B‐cell NHL who were ineligible for HDT.

show abstract

Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents

Cited by 113 publications

References 253 publications

Oxytocin and Neuroprotective Effects

Oxytocin and Neuroprotective Effects

Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β-catenin and TGF-β signaling

Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

Contact Info

Product

Resources

About